Zobrazeno 1 - 10
of 312
pro vyhledávání: '"Rodney H Falk"'
Autor:
Jian Guan, Shikha Mishra, Yiling Qiu, Jianru Shi, Kyle Trudeau, Guy Las, Marc Liesa, Orian S Shirihai, Lawreen H Connors, David C Seldin, Rodney H Falk, Calum A MacRae, Ronglih Liao
Publikováno v:
EMBO Molecular Medicine, Vol 7, Iss 5, Pp 688-688 (2015)
Externí odkaz:
https://doaj.org/article/ce3331e289de475dae37ee8418bae05d
Autor:
Ashutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, Mats Bergström, Swethajit Biswas, Chao Chen, Joseph Cheriyan, Matthew Cleveland, Louise Cookson, Paul Galette, Robert L. Janiczek, Raymond Y. Kwong, Mary Ann Lukas, Helen Millns, Duncan Richards, Ian Schneider, Scott D. Solomon, Jens Sörensen, James Storey, Douglas Thompson, Guus van Dongen, Danielle J. Vugts, Anders Wall, Gerhard Wikström, Rodney H. Falk
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-16 (2022)
Abstract Background In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloi
Externí odkaz:
https://doaj.org/article/a733adacf3434f19a23e0e826ad2a704
Autor:
Jessica Laird, BA, Rodney H. Falk, MD, Melissa Coyle, PharmD, CSP, Sarah A.M. Cuddy, MB BCH, BAO
Publikováno v:
JACC: Case Reports, Vol 2, Iss 15, Pp 2372-2375 (2020)
An 85-year-old women with transthyretin cardiac amyloidosis presented with generalized weakness, elevated liver function test levels, and creatinine kinase consistent with rhabdomyolysis 1 week after starting tafamidis. She was already taking atorvas
Externí odkaz:
https://doaj.org/article/ede6caadbc6c4c7ab569d7547c53f4e8
Publikováno v:
JACC. CardioOncology, Vol 2, Iss 2, Pp 232-235 (2020)
Externí odkaz:
https://doaj.org/article/9c1d885b7f5940b1a21ab8bcbf9c47bb
Autor:
Sarah AM Cuddy, Yesh Datar, Gavin Ovsak, Sunil Saith, Sean P. Murphy, Camden P. Bay, Mia Haddad, Brian Lilleness, Varsha Muralidhar, Alexandra Pipilas, Jacqueline Vuong, Eric Guardino, Mathew S. Maurer, Frederick L. Ruberg, Rodney H. Falk, Sharmila Dorbala
Publikováno v:
Circulation. Cardiovascular imaging. 15(11)
Background: Echocardiographic deformation-based ratios and novel multi-parametric scores have been suggested to discriminate transthyretin cardiac amyloidosis (ATTR-CM) from other causes of increased left ventricular wall thickness among patients ref
Publikováno v:
European Journal of Heart Failure. 25:525-527
Autor:
Senthil Selvaraj, Brian L. Claggett, C. Cristina Quarta, Bing Yu, Riccardo M. Inciardi, Joel N. Buxbaum, Thomas H. Mosley, Amil M. Shah, Sharmila Dorbala, Rodney H. Falk, Scott D. Solomon
Publikováno v:
JAMA Cardiology.
ImportanceHereditary transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure (HF) with distinct treatment. The amyloidogenic pV142I (V122I) variant is present in 3% to 4% of Black individuals in the US and increases the
Autor:
Yiu Ming Khor, Sarah A. M. Cuddy, Vasvi Singh, Rodney H. Falk, Marcelo F. Di Carli, Sharmila Dorbala
Publikováno v:
Radiology. 306
Autor:
Gerard T Giblin, Sarah A M Cuddy, Esther González-López, Alanna Sewell, Amanda Murphy, Sharmila Dorbala, Rodney H Falk
Publikováno v:
European Heart Journal - Cardiovascular Imaging. 23:1029-1039
Aims In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), the effect of tafamidis on myocardial function using serial speckle tracking echocardiography has not been reported. The purpose of this study was to describe the natural history o
Publikováno v:
JACC: CardioOncology
Background Transthyretin amyloid (ATTR) cardiomyopathy is slowed by tafamidis, which stabilizes the TTR molecule and reduces the formation of amyloidogenic oligomers. Stabilizers in clinical doses raise serum TTR, which may be a surrogate for the deg